Physician profile
John Okamoto
NPI 1760462956
$15,332.43
in general payments reported to CMS, 2019-2025
30 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,325 · 2020: $3,020 · 2021: $2,506 · 2022: $2,850 · 2023: $1,317 · 2024: $1,617 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,630.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,729.14 | 2019-2025 | Dailies Total1, Precision 1, Clareon |
| Coopervision INC. | $2,292.94 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Onefit Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,810.31 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,108.42 | 2022-2025 | Infuse, Miebo, Xiidra |
| Biotissue Holdings INC. | $804.80 | 2019-2025 | |
| Sight Sciences, INC. | $328.17 | 2021-2023 | Tearcare System |
| Allergan, INC. | $324.46 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $306.22 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $274.72 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $257.93 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $235.45 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $233.48 | 2019-2022 | |
| Rxsight INC | $225.67 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Harrow Eye, LLC | $198.81 | 2025 | Vevye |
| Glaukos Corporation | $172.86 | 2021-2025 | Idosetr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $138.31 | 2019 | |
| Abbvie INC. | $138.27 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $131.14 | 2022-2024 | Acthar |
| Lumenis Be INC | $130.31 | 2024 | Optilight |
| Abb Con-Cise Optical Group LLC | $128.22 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $94.34 | 2019-2022 | |
| Genentech USA, INC. | $54.11 | 2019 | |
| Kala Pharmaceuticals, INC. | $39.15 | 2021 | |
| Dompe US, INC. | $38.15 | 2024-2025 | Oxervate |
| Maculogix, INC. | $34.91 | 2019-2021 | |
| Topcon Healthcare, INC. | $25.10 | 2024 | |
| Lkc Technologies, INC. | $24.99 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Horizon Therapeutics Plc | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Okamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.